Join to View Full Profile
3601 Pierce AveNashville, TN 37232
Phone+1 615-936-2000
Fax+1 615-343-3212
Dr. Abramson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2000
Certifications & Licensure
TN State Medical License 2020 - 2027
AL State Medical License 2020 - 2020
PA State Medical License 2003 - 2008
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification StarPanel, Vanderbilt University, 2012, 2014-2015
Clinical Trials
- Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer Start of enrollment: 2011 Feb 01
- A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Start of enrollment: 2011 Sep 01
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Publications & Presentations
PubMed
- Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, Vandana G Abramson, Adam Brufsky
Journal of the National Cancer Institute. 2026-01-01 - 10 citationsNCCN Guidelines® Insights: Breast Cancer, Version 5.2025.William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft
Journal of the National Comprehensive Cancer Network. 2025-11-01 - 1 citationsOptimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of D...Dario Trapani, Qingchun Jin, Kathy D Miller, Hope S Rugo, Katherine E Reeder-Hayes
Clinical Breast Cancer. 2025-06-01
Press Mentions
21 Oncology Leaders on the Innovations Transforming Breast Cancer CareOctober 29th, 2025- Including Biomarkers and Patient Preference in Treatment DecisionsMarch 24th, 2025
- Will Palbociclib or Ribociclibw Boost PFS?March 18th, 2025
Grant Support
- Pet-Mri For Assessing Treatment Response In Breast Cancer Clinical TrialsNational Cancer Institute2010–2012
- AKT Inhibitor Mk-2206 For Breast Cancers With A PIK3CA Mutation AND/OR PTEN LossNational Cancer Institute2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
